S. 4031: Innovative Therapies Centers of Excellence Act

The Innovative Therapies Centers of Excellence Act aims to establish specialized centers within the Department of Veterans Affairs (VA) that focus on research and treatment using innovative therapies for various mental health and chronic conditions affecting veterans. Here are the key provisions of the bill:

Establishment of Innovative Therapies Centers

The Secretary of Veterans Affairs is tasked with selecting at least five medical facilities within the VA to be designated as Innovative Therapies Centers of Excellence. These facilities will be established and operated to provide specialized care focused on innovative treatment methods.

Geographic Distribution

The selection process for these centers must ensure that they are spread out geographically, allowing better access for veterans across different regions.

Criteria for Designation

To qualify for designation, facilities must meet several requirements, including:

• Having proposals that pass peer review for scientific and clinical merit.
• Arranging education and training partnerships with accredited medical schools, schools of psychiatry, and schools of social work.
• Attracting capable scientists for medical research efforts.
• Forming advisory committees that include veterans and medical representatives.
• Effectively evaluating center activities.
• Coordinating educational and clinical activities across the VA medical system.
• Building a consortium of providers to ensure state-of-the-art care.
• Creating a national data repository for innovative therapy outcomes.

Peer Review Panel

A peer review panel will be established to assess the scientific and clinical merit of proposals for new centers. This panel will comprise experts in innovative therapies and will provide feedback on the submitted proposals.

Annual Reporting

Starting two years after the bill's enactment, the Under Secretary for Health must submit annual reports to Congress detailing the activities, findings, and recommendations from the centers established under this act.

Funding

The bill authorizes funding of $30 million for each fiscal year to support the centers. Additional funds may be allocated from existing appropriations for medical services and research within the VA.

Definitions

The bill defines "covered conditions" that centers will address, which include:

• Anxiety
• Bipolar disorder
• Chronic pain
• Depression
• Parkinson’s disease
• Post-traumatic stress disorder
• Substance use disorder
• Other conditions as determined by the Under Secretary for Health

It also defines "innovative therapy" to include treatments such as:

• 3,4-Methylenedioxy-methamphetamine (MDMA)
• 5-Methoxy-N,N-dimethyltryptamine
• Ibogaine
• Ketamine
• Psilocybin
• Other therapies as designated by the Under Secretary for Health

Relevant Companies

• NUMN - Numinus Wellness Inc. focuses on research and treatment using psychedelic substances in mental health therapy and may be affected by the expanded research opportunities and partnerships with the VA.
• COMP - Compass Pathways PLC is engaged in developing psychedelic therapies for mental health and could benefit from collaborations and recognition through the centers established by this bill.